IP Library Granted Patent US 8,729,120
Granted Patent B2
US 8,729,120 · App. 11/666,521 · Granted May 20, 2014

Adjunctive therapy for depression

Inventor: Jonathan Sporn (Princeton, NJ)
Assignee: SK Biopharmaceuticals Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,729,120
App. No.
11/666,521
Granted
May 20, 2014
Kind
B2
Abstract

This invention is directed to a method of treating depression in a subject, comprising the step of administering a therapeutically effective amount of a conventional antidepressant and, in addition, administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member Rx selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R 1 and R 2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R 1 and R 2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.

Claims (14)

1. A method for treating depression in a subject comprising:

administering to a subject in need of such treatment a therapeutically effective amount of an antidepressant selected from the group consisting of fluoxetine, amitriptyline, clomipramine, doxepin, imipramine, trimipramine and a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a compound of Formula Ib:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound of Formula Ib is an enantiomer.

3. The method of claim 2 , wherein the enantiomer is a (D) enantiomer.

4. The method of claim 3 , wherein the (D) enantiomer predominates to the extent of about 90% or greater.

5. The method of claim 3 , wherein the (D) enantiomer predominates to the extent of about 98% or greater.

6. The method of claim 1 , wherein the antidepressant is fluoxetine or amitriptyline.

7. The method of claim 1 , wherein the method reduces a side effect of the antidepressant.

8. The method of claim 1 , wherein the antidepressant is administered at a dose smaller than a recommended starting dose.

9. The method of claim 1 , wherein the therapeutically effective amount of the compound of Formula lb is from about 0.01 mg/kg/dose to about 300 mg/kg/dose.

10. The method of claim 1 , wherein the compound of Formula lb is administered at a dose of from 1.0 mg/day to about 100.00 mg/day.

11. The method of claim 1 , wherein the compound of Formula Ib is administered orally or parenterally.

12. The method of claim 1 , wherein the compound of Formula Ib is administered in a form of tablet.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: SK HOLDINGS CO., LTD.
To: SK BIOPHARMACEUTICALS CO., LTD.
Reel/Frame 027558/0316 →
CORRECTIVE ASSIGNMENT TO CORRECT THE COUNTRY OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 020156 FRAME 0012. ASSIGNOR(S) HEREBY CONFIRMS THE SK CORPORATION TO SK HOLDINGS CO., LTD.. Recorded Jun 26, 2008
From: SK CORPORATION
To: SK HOLDINGS CO, LTD.
Reel/Frame 021147/0611 →
CHANGE OF NAME Recorded Nov 19, 2007
From: SK CORPORATION
To: SK HOLDINGS CO., LTD.
Reel/Frame 020156/0012 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2007
From: JANSSEN PHARMACEUTICA, N.V.
To: SK CORPORATION
Reel/Frame 019264/0467 →
Continuity (2)
Provisional Application 60623044 · Oct 28, 2004
Related Publication 20080039529A1 · Feb 14, 2008